New medication combined with standard chemotherapy for advanced pancreatic cancer

Plain-English translation of NCT06079346 on ClinicalTrials.gov ↗ · Source last updated August 2024 · Translation generated July 2026 · How we translate trials

Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.

What is this trial?

This study is testing whether a new medication called , given alongside standard chemotherapy drugs (), can help people with advanced pancreatic cancer live longer and healthier lives. Right now, the standard treatment is the chemotherapy combination alone. Researchers want to see if adding this new medication makes the treatment work better.

Pancreatic cancer is one of the most serious cancers, and current treatments help some patients but not enough. This medication is designed to work in a new way to fight the cancer, and scientists hope that combining it with existing chemotherapy will give patients a better chance of survival.

Do you qualify?

You likely qualify if…

you have been diagnosed with advanced pancreatic adenocarcinoma (pancreatic cancer) that cannot be removed by surgery or has spread to other parts of your body
you are at least 18 years old
you are in good enough overall health to handle the treatment (measured by an ECOG score of 0–1, meaning you can still do most normal activities)
you have adequate organ function, meaning your blood counts, liver, and kidney function are healthy enough for chemotherapy
you have a life expectancy of at least 3 months according to your doctor
if you are a woman of childbearing age, you are willing to use reliable birth control during and for 9 months after the study

You likely don't qualify if…

you have a type of pancreatic cancer other than adenocarcinoma (such as islet cell tumors or certain lymphomas)
your overall health has gotten noticeably worse between your screening visit and the time you would start the study
you are currently taking a blood thinner called Coumadin and are not willing to switch to a different blood thinner
you are pregnant or breastfeeding
your organ function (blood counts, liver, or kidney tests) is too low to safely receive chemotherapy

What participation looks like

If you join this trial, you will be randomly assigned to receive either the new medication () plus standard chemotherapy, or standard chemotherapy alone. The treatment happens in 14-day cycles: chemotherapy starts on Day 1, and if you're in the combination group, you'll receive the new medication on Days 4–7. You'll visit the clinic regularly for infusions, blood tests, and check-ups to see how the treatment is working and to monitor for any side effects. The study will continue until your cancer progresses or you and your doctor decide to stop.

AI-generated summary from trial data · Jul 21, 2026 · Not medical advice

Trial locations(2 sites)

United States

Karmanos Cancer Center, Detroit, Michigan

Baylor College of Medicine, Houston, Texas